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Abstract
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that influences neuronal plasticity throughout life.
Emergence from a vegetative state (VS) after a traumatic brain injury (TBI) implies that the brain undergoes
plastic changes. A common polymorphism in the BDNF gene—BDNF Val66Met (referred to herein as
BDNFMet)—impairs cognitive function in healthy subjects. The aim of this study was to determine whether the
BDNFMet polymorphism plays a role in the recovery of consciousness and cognitive functions in patients in a VS
after a TBI. Fifty-three patients in a VS 1 month after a TBI were included in the study and genotyped for the
BDNFMet polymorphism. Scores of levels of cognitive functioning (LCF) at 1, 3, 6, and 12 months post-TBI were
retrospectively compared in patients without (Val group), and with (Met group), the BDNFMet polymorphism.
The BDNFMet polymorphism was detected in 20 out of the 53 patients. The mean LCF scores in the Val and Met
groups were 1.6 – 0.5 and 1.4 – 0.5 at 1 month, 2.3 – 0.7 and 2.5 – 1.2 at 3 months, 3.3 – 1.7 and 3.5 – 1.7 at
6 months, and 4 – 1.9 and 3.9 – 1.8 at 12 months, respectively ( p > 0.05). The percentages of patients in the Val and
Met groups who emerged from the VS were 36.4% and 30% at 3 months, 66.3% and 70% at 6 months, and 70%
and 87.5% at 12 months ( p > 0.05), respectively. These findings provide evidence that the BDNFMet polymor-
phism is not involved in cognitive improvement in patients with a VS following TBI. Future studies should focus
on the role of other BDNF polymorphisms in the recovery from a VS.
Key words: disorders of consciousness; genetic factors; levels of cognitive functioning; traumatic brain injury;
vegetative state
Introduction
After a period of coma due to a severe traumatic braininjury (TBI), patients who do not recover consciousness
or die develop a dramatic condition known as vegetative state
(VS). The hallmark feature of a VS is a dissociation between
the two cardinal elements of consciousness: awareness and
wakefulness. Indeed, patients in a VS seem to be awake, but
lack any sign of awareness of themselves or of their envi-
ronment (Monti et al., 2010). The threemain factors associated
with recovery from a VS include: (1) the type of brain injury,
(2) the patient’s age, and (3) the time spent in a VS (Monti
et al., 2010; Royal College of Physicians, 2003; The Multi-
Society Task Force on PVS, 1994a,1994b). Patients with a VS
caused by a TBI have better outcomes in terms of recovery
of independence (24% versus 4%) and consciousness (52%
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versus 13%) than those with non-traumatic injuries (due to
cerebral anoxia or stroke; Monti et al., 2010; Royal College of
Physicians, 2003; The Multi-Society Task Force on PVS,
1994a,1994b). The reason for this improved outcome is not
well understood. It may be related to different neuropatho-
logical findings. Indeed, the most common structural abnor-
mality identified in patients in a VS after a TBI is a diffuse
axonal injury, while in non-traumatic brain injuries diffuse
ischemic damage in the neocortex is predominant (Adams
et al., 2000). In addition, the better outcomes associated with
TBIs may be related to the younger age of patients who typ-
ically suffer from TBIs (in comparison, for instance, to patients
with vascular diseases or anoxia); notably, increased age
worsens the recovery rate from a VS (The Multi-Society Task
Force on PVS, 1994b). The third main factor related to con-
sciousness improvement is the duration of VS itself, which
correlates negatively with the chance of recovering con-
sciousness (Braakman et al., 1998). These factors are valid in
terms of group analyses. However, currently it remains ex-
tremely difficult to make a prognosis regarding consciousness
and cognitive functional recovery in patients in a VS (Hirsch-
berg and Giacino, 2011). This difficulty may at first be ex-
plained by thewide variety of brain injuries that can be caused
during TBIs. Nevertheless, clinical practice suggests that ad-
ditional factors are also probably involved in the outcomes for
these patients. For example, neuroimaging studies have not
uncovered specific features useful for predicting recovery from
a VS, although some functional magnetic resonance imaging
(fMRI) analysesmaydistinguishwhether a patient is in a VS or
not (Owen et al., 2006). The lack of correlation between neu-
roimaging studies and prognosis suggests that patients with
similar brain injuries may have different outcomes.
Emergence from a VS implies that the brain undergoes
changes in plasticity that restore connections and/or func-
tions that existed prior to the traumatic event. Therefore,
individual differences in genetic factors that regulate mecha-
nisms underlying brain plasticity may hypothetically con-
tribute to different outcomes. Polymorphisms in the gene
encoding brain-derived neurotrophic factor (BDNF) are good
candidates for playing this role. BDNF is a neurotrophin that
performs a critical function in the modulation of synaptic ef-
ficacy (i.e., long-term potentiation [LTP]) involved in learning,
memory, and adaptive behavior (Kleim et al., 2006; Poo, 2001;
Tyler et al., 2002). Current knowledge concerning BDNF
function shows that it is associated with intracellular sig-
naling related to neuronal protection, synaptic function
(glutamate-dependent spine and dendritic growth, synapse
formation, stabilization, and potentiation), and morpho-
logical changes affecting neural development and function
(Numakawa et al., 2010; Yoshii and Constantine-Paton, 2010).
More specifically, in cellular and animal models, BDNF is
involved in mechanisms underlying LTP induction and
maintenance by activating latent synapses (Shen et al., 2006),
and modulating cytoskeletal functions (Rex et al., 2007;
Yano et al., 2006). The BDNF gene (gene ID 627 located on
chromosome 11p13) has a common polymorphism (rs6265,
dbSNP NCBI database), that leads to an amino acid substi-
tution (valine to methionine) at codon 66 (Val66Met, referred
to herein as the BDNFMet polymorphism). This sequence
variant is located in the 5¢ pro-BDNF sequence, which encodes
the precursor peptide (pro-BDNF), that is proteolytically
cleaved to form the mature protein (Seidah et al., 1996).
Although this BDNFMet polymorphism does not affect tran-
scription and translation processes or mature BDNF protein
function, it has been shown to dramatically alter the intra-
cellular trafficking and packaging of pro-BDNF, and thus the
regulated secretion of the mature peptide (Chen et al., 2004).
The BDNFMet polymorphism is relatively common and is
predicted to be present in 25–36% of the Caucasian population
(Pivac et al., 2009; Shimizu et al., 2004).
The BDNFMet polymorphism is linked to some anatomical
consequences in healthy subjects, and it has been associated
with reduced hippocampal volume, decreased prefrontal
cortex gray matter, and age-dependent modifications to the
corpus callosum (Bueller et al., 2006; Nemoto et al., 2006;
Pezawas et al., 2004; Szeszko et al., 2005). These findings have
led to the hypothesis that BDNF-dependent plasticity may
have some functional consequences in healthy subjects. In-
deed, it has been demonstrated that the BDNFMet polymor-
phism affects memory, cognitive function, and learning (Egan
et al., 2003; Miyajima et al., 2008; Soliman et al., 2010).
BDNF may also influence the phenotypic expression of
many diseases. For example, BDNF serum levels may be as-
sociated with cognitive impairment in schizophrenia (Zhang
et al., 2012), or illness severity in major depression (Birken-
ha¨ger et al., 2012). Moreover, it has been shown that the
BDNFMet polymorphism may also affect recovery from
hemorrhagic stroke such that it predicts a poor outcome
among patients who survive an aneurysmal subarachnoid
hemorrhage (Siironen et al., 2007). The BDNFMet polymor-
phism has not been assessed previously in patients in a VS
after a TBI, although it was recently demonstrated that other
BDNF polymorphisms (rs7124442 and rs1519480) might be
useful for predicting general intelligence 10–15 years after a
penetrating TBI (Rostami et al., 2011).
Based on these findings, we evaluated whether the
BDNFMet polymorphism plays a role in the recovery of con-
sciousness and cognitive function in patients in a VS after a
TBI. To this end,we assessed the BDNFgenotype in patients in
VS 1 month after a TBI. We used the levels of cognitive func-
tion (LCF) scale (Hagen et al., 1972) to evaluate the recovery of
consciousness and cognitive function. This scale is based on
eight levels: levels 1 and 2 define patients in a VS, while the
other levels denote a progressive improvement of cognitive
function; level 8 describes patients with cognitive function
close to their pre-morbid ability.We retrospectively correlated
the different genotypes with consciousness levels evaluated
with the LCF scale at 1, 3, and 6 months. The chances of re-
gaining awareness in patients in a VS decrease as time passes,
and recovery usually occurs within 6 months. However, in
TBIs this recovery period lasts up to 12months (Royal College
of Physicians, 2003); therefore, we included also data at
12 months when available. The results of this study will help
to clarify whether the BDNFMet polymorphism is a useful
prognostic factor in patients with VS after severe TBI.
Materials and Methods
Patients
This study was conducted with 53 patients who were in
a VS after a TBI (45 males, 8 females; mean age 31.2 – 11.2
years, range 15–55 years; all of Caucasian race), admitted to
five Italian centers specializing in the rehabilitation of post-
traumatic disorders of consciousness (Table 1). Four other
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patients were excluded because of a lack of clinical data or
informed consent. All of the patients underwent standard
neurological/neurosurgical intensive care after the TBI. Thirty-
five patients underwent neurosurgical procedures, such as
decompressive craniectomy (18 patients), hematoma evacua-
tion (14 patients), ventriculoperitoneal shunt placement (13
patients), intracranial pressure monitoring (8 patients), and
temporal pole resection (1 patient), alone or combined (Table
1). Inclusion criteria were the following: (1) age£ 55 years at the
time of the TBI (since people are conventionally considered
elderly after 60 years of age, the age limit of 55 years was
arbitrarily chosen in order to minimize the effects of the aging
brain on recovery); (2) in a VS 1 month after TBI, according to
current diagnostic criteria (Bates, 2005; Royal College of Phy-
sicians, 2003; The Multi-Society Task Force on PVS, 1994a); (3)
LCF score of 1 or 2 at 1month post-TBI; (4) available LCF scores
at 1, 3 and 6 months post-TBI; and (5) no history of any neu-
rological or psychiatric disease before the TBI.
The patients’ relatives and/or legal guardians gave their
written informed consent; the study and the consent proce-
dure were performed according to the Helsinki Declaration,
and were approved by the ethical committee of the coordi-
nating center (Fondazione Istituto San Raffaele G. Giglio,
Cefalu` [PA], Italy; number of protocol: BDNF/2010); the
protocol was then ratified by the ethical committees of the
other centers involved in the study.
Clinical evaluation
LCF scores at 1, 3, and 6 months were retrospectively ob-
tained from clinical documentation; if the scores were not
known with certainty, the patient was not included in the
study. Clinical documentation of the LCF score at 12 months
was available for 36 out of the 53 patients and these data were
also analyzed. The diagnosis of VS and LCF assessments were
made in all patients by a multidisciplinary team (neurologist,
neuropsychologist, and speech therapist). Patients were in-
cluded if the LCF scores at 1, 3, 6, and 12 months remained
unchanged at the clinical evaluation performed on two con-
secutive days. Persistence of VS at 3, 6, and 12 months was
defined according to clinical criteria (Bates, 2005; Royal Col-
lege of Physicians, 2003; TheMulti-Society Task Force on PVS,
1994a), and confirmed by an LCF score of 1 or 2 in all cases.
The LCF scale defines eight levels of cognitive impairment (1:
no response to stimuli; 2: generalized response; 3: localized
response; 4: confused-agitated; 5: confused, inappropriate, non-
agitated; 6: confused-appropriate; 7: automatic-appropriate;
and 8: purposeful-appropriate; Hagen et al., 1972). All of the
investigators collecting the clinical data were blinded to the
results of the genetic analysis. Likewise, investigators who
carried out the genetic analyses (L.M. andV.B.) were blinded to
the patients’ LCF scores. Finally, the statistical analyses were
performed by a different researcher (S.B.).
Genetic analysis
Genotyping. Genetic analysis was performed on periph-
eral blood samples collected from five Italian centers after the
patients were recruited. Blood samples were sent to the co-
ordinating center (Rehabilitation Department, Fondazione
Istituto ‘‘San Raffaele–G. Giglio,’’ Cefalu`, Italy), and then they
were genotyped by the Laboratorio di Tecnologie Oncolo-
giche (LATO)-HSR Giglio, Cefalu`, Italy.
BDNF genotypes were assessed in all patients in order to
identify carriers of the Val66Met polymorphism (rs6265)
within the coding region of the BDNF gene, which is derived
from a base substitution at codon 66 (G/A). To genotype the
BDNFMet polymorphism, a restriction fragment length poly-
morphism (RFLP) assay and sequencing analysis were used.
Total genomic DNA was extracted from peripheral blood
using the QIAamp DNA blood mini-kit according to the
manufacturer’s specifications (Qiagen, Valencia, CA). Geno-
mic DNA was PCR amplified using BDNF primers designed
using Primer3 software (http//fokker.wi.mit.edu/primer3;
BDNF forward: 5¢-aaagaagcaaacatccgaggac-3¢ and BDNF re-
verse 5¢-attcctccagcagaaagagaag-3¢). PCR reactions were per-
formed using 50 ng of genomic DNA in a total volume of
50lL containing 1·PCR Gold Buffer, 1.5mM of MgCl2,
200lM dNTPs, 200 nM of forward and reverse BDNF primer
mix, and 1.25U of AmpliTaqGoldDNAPolymerase (Applied
Biosystems, Foster City, CA). The thermal cycle profile em-
ployed a 5-min denaturing step at 94C, followed by 35 cycles
at 94C for 45 sec, 58C for 45 sec, 72C for 45 sec, and a final
extension step of 5min at 72C. The quality and concentration
of the PCR products of 274 bpwere assessed using the Agilent
2100 Bioanalyzer according to the manufacturer’s standard
protocol (Agilent Technologies, Santa Clara, CA).
BDNFMet RFLP assay. An aliquot of the PCR product
was digestedwith 10U ofHsp92II restriction enzyme (RE) in a
50-lL volume containing 1 ·RE buffer and 5lg of bovine
serum albumin (Promega, Fitchburg,WI) for 2 h at 37C.After
heat inactivation by incubation at 65C for 15min, the di-
gested products were purified with the QIAquick PCR puri-
fication kit according to the manufacturer’s specifications
(Qiagen). RFLP analysis of Val66Met was carried out using
the DNA 1000 kit in the Agilent 2100 Bioanalyzer. The Val-
homozygous samples (G/G at codon 66) produced two visi-
ble products of 216 bp and 58 bp, whereas Met-homozygous
samples (A/A at codon 66) produced three visible products of
139 bp, 77 bp, and 58 bp. Finally, heterozygous samples (G/A
at codon 66) produced four fragments of 216 bp, 139 bp, 77 bp,
and 58 bp.
BDNF sequencing. To confirm the RFLP genotyping
data, the PCR products were sequenced. An aliquot of the
PCR amplicon was purified using the QIAquick PCR purifi-
cation kit according to the manufacturer’s specifications
(Qiagen). The concentration and quality of the DNA samples
were determined using a NanoDrop ND-1000 Spectro-
photometer. DNA sequencing was performed by MWG
Biotech Laboratories (Ebersberg, Germany). In all cases, the
sequencing results confirmed the previous data.
Statistical analysis
The patients were first divided into two groups (the Val
group and the Met group) according to their genotype. Since
the prevalence of the individuals homozygous for the
BDNFMet polymorphism is low among Caucasians (approxi-
mately 3.4%; Pivac et al., 2009), the Met group included pa-
tients who were either heterozygous or homozygous for the
BDNFMet polymorphism. The preliminary sample size anal-
ysis was made considering an expected mean LCF value at
6 months of 3.3 for the Val group, an expected mean LCF
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value of 2.5 for the Met group, a common standard deviation
of 1.5, an alpha error level of 5%, and a beta error level of 50%.
Based on these criteria, the required sample size was 38 pa-
tients (19 patients for each group). However, the effective
sample size of the study was larger (53 patients).
Differences in demographic data were assessed by the
Student’s t-test. Fisher’s exact test was used to evaluate
whether the number of patients who emerged from a VS (i.e.,
with a LCF score ‡ 3) at 3, 6, and 12 months was different in
the Val and Met groups. Likewise, we compared the number
of patients whose LCF scores improved at 3 months (with
respect to 1 month), 6 months (with respect to 3 months), and
12 months (with respect to 6 months), in the Val and Met
groups. Then the main statistical analysis was chosen to
evaluate whether the BDNF genotypes influence LCF scores
at 1, 3, 6, and 12 months post-TBI. Thus, we used a two-way
repeated-measures analysis of variance (ANOVA) with the
factor group (Val group versus Met group) as the between-
subject factor, and the factor time (LCF score at 1month versus
LCF scores at 3, 6, and 12months) as the within-subject factor.
Mauchly’s test was used to evaluate the sphericity of vari-
ances, and the Greenhouse-Geisser method was applied if
necessary to correct for non-sphericity. Conditional on a sig-
nificant F value, post-hoc comparisons were performed using
the Tukey honest significant difference test.
For all analyses, p< 0.05 was considered statistically sig-
nificant. Data are given as mean values – standard deviation.
Results
RFLP assays and sequencing analyses revealed the Val/Val
genotype in 33 patients (62.3%), whereas 20 patients (37.7%)
were carriers of the BDNFMet polymorphism (including 17
heterozygotes and 3 homozygotes). The mean age was
31.5 – 11.2 years in the Val group, and 30.8 – 11.4 years in the
Met group ( p = 0.8). LCF scores at 12 months were optional,
and data for analysis were available in 36 (67.9%) of the 53
patients (20 in the Val group and 16 in the Met group, in-
cluding 14 heterozygotes and 2 homozygotes).
Mean LCF scores in the Val and Met groups were 1.6 – 0.5
and 1.4 – 0.5 at 1 month, 2.3 – 0.7 and 2.5 – 1.2 at 3 months,
3.3 – 1.7 and 3.5 – 1.7 at 6 months, and 4 – 1.9 and 3.9 – 1.8 at
12 months, respectively (Fig. 1). The percentages of patients
who emerged from a VS in the Val and Met groups were
36.4% and 30% at 3 months ( p = 0.8), 66.3% and 70% at 6
months ( p = 0.8), and 70% and 87.5% at 12 months ( p= 0.3),
respectively (Table 2A). The percentages of patients who im-
proved their LCF scores in the Val and Met groups were 67%
and 75% at 3 months ( p = 0.8), 48% and 60% at 6 months
( p= 0.6), and 60% and 50% at 12 months ( p= 0.7), respectively
FIG. 1. LCF scores at 1, 3, 6, and 12 months post-TBI in
patients without (Val group) and with (Met group) the
BDNFMet polymorphism. LCF scores at 12 months were
optional, and available for 20 patients in the Val group and
16 patients in the Met group. Vertical bars denote 95% con-
fidence intervals (LCF, level of cognitive functioning; TBI,
traumatic brain injury; BDNF, brain-derived neurotrophic
factor).
Table 2. (A) Number of Patients Emerging (Yes) or Not (No) from a Vegetative State (VS) at 3, 6, and 12 Months
after a Traumatic Brain Injury (TBI) in the Val and Met Groups. (B) Number of Patients Increasing (Yes)
or Not (No) Their LCF Scores at 3, 6, and 12 Months after a TBI in the Val and Met Groups
Patients emerging from
a VS 3 months after a TBI
Patients emerging from
a VS 6 months after a TBI
Patients emerging
from a VS 12 months after a TBI
A Yes No Total Yes No Total Yes No Total
Val group 12 21 33 21 12 33 14 6 20
Met group 6 14 20 14 6 20 14 2 16
Total 18 35 53 35 18 53 28 8 36
Fisher’s exact test p= 0.8 p = 0.8 p= 0.3
Improvement of LCF score
at 3 months versus 1 month
Improvement of LCF score
at 6 months versus 3 months
Improvement of LCF score
at 12 months versus 6 months
B Yes No Total Yes No Total Yes No Total
Val group 22 11 33 16 17 33 12 8 20
Met group 15 5 20 12 8 20 8 8 16
Total 37 16 53 28 25 53 20 16 36
Fisher’s exact test p= 0.8 p = 0.6 p= 0.7
LCF, levels of cognitive functioning; Met group, patients with the BDNFMet polymorphism (homozygous and heterozygous patients); TBI,
traumatic brain injury; Val group, patients without the BDNFMet polymorphism.
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(Table 2B). ANOVA showed a significant effect of the factor
time (F1.9,64.6 = 53.9; p< 0.005), due to an overall improvement
in LCF scores independent of the BDNF genotype ( p < 0.05 for
LCF score at 3 months versus 1 month, LCF score at 6 months
versus 3 months, and LCF score at 12 months versus 6
months). Indeed, the factor group (F1,34 = 0.09; p= 0.8), and the
interaction group · time (F1.9,64.6 = 0.7; p = 0.5) did not show any
significant differences between the Val and Met groups.
Discussion
In the current study,we provide evidence that the BDNFMet
polymorphism is not involved in either recovery of con-
sciousness or in the cognitive improvement of patients in VS
after a severe TBI. Indeed, the percentages of patients who
emerged from a VS at 3, 6, and 12 months after TBI did not
differ between the Val and Met groups. Likewise, LCF scores
at 1, 3, 6, and 12 months post-TBI were similar in both groups
of patients, independent of the BDNFMet polymorphism.
To our knowledge, this is the first study evaluating the role
of a genetic factor in the recovery of cognitive function in a
large population of patients in a VS. Although the results
rebut our initial hypothesis, some interesting considerations
may be drawn from our data. Indeed, the BDNFMet poly-
morphism does not seem to be involved in the cerebral
mechanisms underlying cognitive improvement and emer-
gence from a VS after a severe TBI. BDNF protein is widely
distributed in the adult brain in almost all cortical areas, as
well as in several subcortical and spinal cord regions (Baker-
Herman et al., 2004), and throughout life it influences the
proliferation, differentiation, and functional activity of neu-
ronal cells that underlie cognitive function (Kleim et al., 2006;
Poo, 2001; Tyler et al., 2002). With regard to LTP, BDNF-
dependent mechanisms involved in cognitive tasks have been
well studied, both in healthy subjects (Egan et al., 2003;
Miyajima et al., 2008; Soliman et al., 2010), and in pathological
conditions such as mood disorders (Chen et al., 2006). In
particular, it has been reported that the BDNFMet polymor-
phism may lead to a reduction in some cognitive functions in
normal subjects (Hariri et al., 2003; Miyajima et al., 2008), or
may predispose to major depression (Frodl et al., 2007), or
anxiety disorders (Montag et al., 2010). However, unlike most
other studies, we did not evaluate whether the BDNFMet
polymorphism affects normal performance or predisposes to
pathological conditions; rather, we investigated whether the
BDNFMet polymorphism influences the recovery of cognitive
function. In other words, the presence of the BDNFMet poly-
morphism may play distinct roles in the normal cognitive
functions of healthy subjects (or predispose them to psychi-
atric disorders), and in the recovery of cognitive function after
a severe TBI.
Although recovery from a VS may be considered a general
process related to brain plasticity, a main factor that may
explain the lack of correlation between BDNF genotype and
outcomes of patients in a VS is the wide heterogeneity of brain
injuries (see CT and MRI findings in Table 1). To reduce the
variability in our population, we did not include patients who
were in a VS due to a non-traumatic brain injury (e.g., patients
in a VS after anoxic or vascular brain damage). Nevertheless,
no two brain lesions associated with a TBI are identical, and
there is a wide range of neuropathological findings in dis-
abled head-injury survivors (Adams et al., 2011). Therefore, it
may be useful to adopt even more stringent inclusion criteria
and recruit patients with more homogeneous cerebral dam-
age (for example, only those with a similar degree of diffuse
axonal damage, or with brain injury due to anoxia) in future
studies of correlations with genetic factors. In addition, we
studied patients in a VS 1 month after TBI, even though
unfavorable genetic factors may have already predisposed
these patients to develop a VS after the comatose phase.
Therefore, in future studies it may be interesting to genotype
patients in an earlier phase (e.g., during a coma after a TBI), in
order to evaluate whether some factors predispose them to
develop a VS.
A potential limitation of our study is the scale we employed
for our clinical evaluation. We chose the LCF scale because it
was adopted by all participant centers and because it assesses
only cognitive functions—and not, for instance, motor tasks—
that were the target of the study. Moreover, the LCF scale has
recently shown good correlation with some neurophysiolog-
ical parameters in patients in a VS (Bagnato et al., 2010; Boc-
cagni et al., 2011; Fingelkurts et al., 2012, in press). However,
the LCF scale provides only an overall evaluation of cognitive
functioning in these patients. Therefore it would be interesting
to assess specific cognitive functions (e.g., memory, attention,
and problem-solving) in patients recovering from a VS.
In the current study, carried out in Caucasian patients, we
found a low occurrence rate of homozygosity for the BDNFMet
polymorphism (3 patients, 5.5% of the total), which is in ac-
cord with its expected prevalence (3.4%; Pivac et al., 2009).
Therefore, as in other recent studies (Siironen et al., 2007;
Soliman et al., 2010), we grouped patients with Val/Met and
Met/Met genotypes. As a result, we cannot exclude the pos-
sibility that homozygous patients may have a worse outcome;
this point should be further investigated in studies conducted
in populations with a higher BDNFMet polymorphism rate,
such as Asian populations (Pivac et al., 2009).
Due to its widespread diffusion in the central nervous sys-
tem, and on the basis of pathophysiological knowledge from
animal models, BDNF has been proposed as a therapeutic tool
in different neurological diseases such as Parkinson’s disease,
Alzheimer’s disease, and spinal cord injuries (Blesch and
Tuszynski, 2007; Nagahara et al., 2009; Tsukahara et al., 1995).
However, the pathophysiology and physiological mecha-
nisms underlying recovery in VS remain largely unknown,
and animal models are not available to study this condition.
The results of the current study provide evidence that the
BDNFMet polymorphism is not involved in the recovery of
consciousness and cognitive improvement of patients in a VS
after severe TBI. However, future studies should focus on the
role of other BDNF polymorphisms in the cerebral reorgani-
zation associated with recovery in these patients.
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